Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (768)	4/2/2002 9:07:36 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

Tuesday April 2, 7:01 am Eastern Time Press Release SOURCE: Axiom Biotechnologies Inc. UCB and Axiom Extend Collaboration in Drug Discovery UCB S.A. (Pharma Sector) and Axiom Biotechnologies Inc. Have Extended Their Collaboration to Discover New Drugs for The Treatment of Allergic Diseases and Asthma SAN DIEGO--(BW HealthWire)--April 2, 2002-- Axiom Biotechnologies Inc. announced that it is extending its collaboration with the UCB S.A. (Pharma Sector) to discover new drugs for the treatment of allergic diseases and asthma. Axiom is using its proprietary physiogenomics approach in this collaboration to characterize particular types of cellular receptors that are of interest for UCB's programs, and to find drug candidates active at these receptors. ``UCB has been an excellent drug discovery partner, and we look forward to continuing the relationship,'' stated Pandi Veerapandian, Axiom's CEO. ``This Agreement is consistent with our goal of using our unique approach in strategic partnerships with leading drug discovery companies.'' Dr. Roy Massingham, UCB's Head of Research (Europe), said ``We are very pleased to be working with the Axiom team and to formalize the initial collaboration which has been running for the past year. Access to Axiom's technologies and their human cell bank will provide UCB with high content information on our compounds at a very early stage. Our initial focus will be on GPCR targets identified from other approaches. The integrated technology platform will provide both rapid screening and profiling and/or in depth characterization of related compounds on signaling cascades based on cellular assays.'' The two companies had already been working together under a bridging agreement. The financial terms of the new agreement include an upfront payment, research support, milestone payments, and bonuses, although the amounts of each were not disclosed. The one-year contract is extendable for a second year. About UCB: UCB is a world scale pharmaceutical and chemical group which is active in three industrial sectors: the Pharma sector, the Chemical sector and the Film sector. The aims of the Pharma sector are the research, production and marketing of medical products on prescription, covering the fields of the immuno-allergy and the central nervous system. About Axiom: Axiom Biotechnologies is a privately-held biopharmaceutical company focused on the more rapid production of drugs that are more effective and safer, through the application of its proprietary physiogenomics approach. This approach incorporates Axiom's Human Cell Bank, a large collection of pharmacologically and genetically characterized human cells, as well as proprietary cell assay technologies. -------------------------------------------------------------------------------- Contact: Axiom Biotechnologies Inc. Pandi Veerapandian, President & CEO / Michael Kozlowski, Chief Operating Officer 858/455-4500 www.axiombio.com or UCB's Head Research Europe Roy Massingham, 32 2 386 25 15 or UCB's Head in Vitro Pharmacology Pierre Chatelain, 32 2 386 26 00